Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice - PubMed (original) (raw)

Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice

Masatoshi Inden et al. Neurochem Int. 2009 Dec.

Abstract

Pramipexole, an agonist for dopamine (DA) D2/D3-receptors, has been used to treat both early and advanced Parkinson's disease (PD). In this study, we examined the effect of pramipexole on DA neurons in a PD model of C57BL/6 mice, which were treated with rotenone (30 mg/kg, p.o.) daily for 28 days. Pramipexole (1 mg/kg, i.p.) was injected daily 30 min before each oral administration of rotenone. Chronic oral administration of rotenone caused a loss of DA neurons in the substantia nigra pars compacta (SNpc), motor deficits and the up-regulation of alpha-synuclein immunoreactivity in some surviving DA neurons. Pramipexole inhibited rotenone-induced DA neuronal death and motor deficits, and reduced immunoreactivity for alpha-synuclein. In addition, pramipexole inhibited the in vitro oligomerization of human wild-type alpha-synuclein by H(2)O(2)plus cytochrome c. To examine the neuroprotective effect of pramipexole against oxidative stress, we used a DJ-1-knockdown SH-SY5Y cell line and electron spin resonance (ESR) spectrometry. Simultaneous treatment with H(2)O(2) and pramipexole resulted in the significant protection of DJ-1-knockdown cells against cell death in a concentration-dependent manner. A high concentration of pramipexole directly scavenged hydroxyl radical (*OH) generated from H(2)O(2) and Fe(2+). Furthermore, pramipexole increased Bcl-2 immunoreactivity in DA neurons in the SNpc. These results suggest that pramipexole may protect DA neurons against exposure to rotenone by chronic oral administration, and this effect is mediated by multiple functions including scavenging of *OH and induction of Bcl-2 protein.

PubMed Disclaimer

Similar articles

• Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
  Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa K, Sawada H, Izumi Y, Yamamoto N, Kihara T, Uemura K, Inoue H, Taniguchi T, Akaike A, Takahashi R, Shimohama S. Takeuchi H, et al. J Neurosci Res. 2009 Feb;87(2):576-85. doi: 10.1002/jnr.21869. J Neurosci Res. 2009. PMID: 18803299
• L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
  Saravanan KS, Sindhu KM, Senthilkumar KS, Mohanakumar KP. Saravanan KS, et al. Neurochem Int. 2006 Jul;49(1):28-40. doi: 10.1016/j.neuint.2005.12.016. Epub 2006 Feb 21. Neurochem Int. 2006. PMID: 16490285
• Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.
  Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, Taira T, Ariga H, Shimohama S. Inden M, et al. J Neurochem. 2007 Jun;101(6):1491-1504. doi: 10.1111/j.1471-4159.2006.04440.x. J Neurochem. 2007. PMID: 17459145
• Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
  Albrecht S, Buerger E. Albrecht S, et al. Curr Med Res Opin. 2009 Dec;25(12):2977-87. doi: 10.1185/03007990903364954. Curr Med Res Opin. 2009. PMID: 19842998 Review.
• Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.
  Xiong N, Long X, Xiong J, Jia M, Chen C, Huang J, Ghoorah D, Kong X, Lin Z, Wang T. Xiong N, et al. Crit Rev Toxicol. 2012 Aug;42(7):613-32. doi: 10.3109/10408444.2012.680431. Epub 2012 May 11. Crit Rev Toxicol. 2012. PMID: 22574684 Review.

Cited by

• Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.
  Müller T, Muhlack S. Müller T, et al. J Neural Transm (Vienna). 2014 Jun;121(6):643-8. doi: 10.1007/s00702-013-1155-1. Epub 2014 Jan 5. J Neural Transm (Vienna). 2014. PMID: 24390153
• NF-κB/c-Rel deficiency causes Parkinson's disease-like prodromal symptoms and progressive pathology in mice.
  Parrella E, Bellucci A, Porrini V, Benarese M, Lanzillotta A, Faustini G, Longhena F, Abate G, Uberti D, Pizzi M. Parrella E, et al. Transl Neurodegener. 2019 May 21;8:16. doi: 10.1186/s40035-019-0154-z. eCollection 2019. Transl Neurodegener. 2019. PMID: 31139367 Free PMC article.
• The role of pramipexole in a severe Parkinson's disease model in mice.
  Elhak SG, Ghanem AA, Abdelghaffar H, Eldakroury S, Eltantawy D, Eldosouky S, Salama M. Elhak SG, et al. Ther Adv Neurol Disord. 2010 Nov;3(6):333-7. doi: 10.1177/1756285610389655. Ther Adv Neurol Disord. 2010. PMID: 21179594 Free PMC article.
• Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease.
  Chagraoui A, Di Giovanni G, De Deurwaerdère P. Chagraoui A, et al. Biomolecules. 2022 Feb 1;12(2):243. doi: 10.3390/biom12020243. Biomolecules. 2022. PMID: 35204744 Free PMC article. Review.
• Hydroxysafflor Yellow A Improves Motor Dysfunction in the Rotenone-Induced Mice Model of Parkinson's Disease.
  Wang T, Wang L, Li C, Han B, Wang Z, Li J, Lv Y, Wang S, Fu F. Wang T, et al. Neurochem Res. 2017 May;42(5):1325-1332. doi: 10.1007/s11064-017-2176-1. Epub 2017 Jan 17. Neurochem Res. 2017. PMID: 28097465

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal